





CellTrend GmbH

GESCHÄFTSFÜHRER: DR. HARALD HEIDECKE
IM BIOTECHNOLOGIEPARK • D-14943 LUCKENWALDE • E-MAIL: INFO@CELLTREND.DE
TEL: +49 (0)3371 / 681 290 • FAX: +49 (0)3371 / 681 312

Cell Line Specification Sheet

EAT-TurboFP635

Mouse breast carcinoma (Ehrlich-Lette Ascites) cells expressing far-red fluorescent TurboFP635




SPECIFICATIONS:

Cell Line:	EAT cells expressing far-red fluorescent TurboFP635
Cells/vial:	approximately 5×10^5
Subculturing:	1:2 to 1:3
Medium Renewal:	2 to 3 times per week
Growth Medium:	RPMI-1640 (2,0 g/L NaHCO ₃) + 10 % fetal calf serum (FCS), 2 mM L-Alanyl-L-Glutamine, 1 % Non Essential Amino Acids (NEA)
Freeze Medium:	complete growth medium + 10% FCS, 10% DMSO
mycoplasma-free	
Shipping:	frozen
Storage Recommendation:	Liquid nitrogen
Biosafety Level:	1

INFORMATION:

Organism:	<i>Mus musculus</i> (mouse)
Source:	Organ: breast, disease: adenocarcinoma
Tumorgenetic:	yes
Growth properties:	suspension
Morphology:	spherical
Conditions:	37 °C, 5 % CO ₂
Plasmid:	pTurboFP635-C (Evrogen, Moscow, Russia)



EAT cells expressing far-red fluorescent TurboFP635

EAT (Ehrlich-Lette Ascites, mouse breast adenocarcinoma) cells have been stably transfected to express far-red fluorescent TurboFP635. EAT was established as a malignant mouse breast carcinoma. It is widely used in comparative testing of anti-tumor agents. Due to the biophysical properties of TurboFP635 this cell line is especially favorable for in vivo applications such as bio-imaging of tumor progression in real time (e.g. tracing and measuring of tumors in a living animal).

References

Poulsen KA et al., **Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels.** Am J Physiol Cell Physiol. 2010 Jan;298(1):C14-25. Epub 2009 Oct 21. PubMed: 19846756

Taşkin El et al., **Apoptosis-inducing effects of Morinda citrifolia L. and doxorubicin on the Ehrlich ascites tumor in Balb-c mice.** Cell Biochem Funct. 2009 Dec; 27(8):542-6. PubMed: 19908222


Klein G. **Use of the Ehrlich ascites tumor of mice for quantitative studies on the growth and biochemistry of neoplastic cells.** Cancer. 1950 Nov;3(6):1052-61. No abstract available. PubMed: 14783753

Karzel K. **On a permanent strain of Ehrlich-Ascites tumor cells growing in suspension in vitro.** Med Pharmacol Exp Int J Exp Med. 1965;12:137-144. PubMed: 14283794

FOR NON-HUMAN INVESTIGATIONAL RESEARCH ONLY.

TO BE HANDLED UNDER BIOSAFETY LEVEL 1 CONTAINMENT.

Information derived from ATCC and Cell Lines Service.



This product contains a proprietary nucleic acid from coding for a proprietary fluorescent protein(s) intended to be used for research purpose only, where research purpose means uses or activities (or the results therefrom) that do not directly generate revenue. Any use of the proprietary nucleic acid or protein other than for research use is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

distributed in the US/Canada by:

EAGLE BIOSCIENCES, INC.

20A NW Blvd, Suite 112 Nashua, NH 03063

Phone: 617-419-2019 FAX: 617-419-1110

www.EagleBio.com • info@eaglebio.com



EAGLE
BIOSCIENCES